Our Company

Orphan Drug Designation of GV1001 by FDA for the treatment of Progressive Supranuclear Palsy (US)

Orphan Drug Designation of GV1001 by EMA for the treatment of Progressive Supranuclear Palsy (EU)

FAST TRACK Designation of GV1001 by FDA for the treatment of Progressive Supranuclear Palsy (US)

FDA IND Approval for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (US)

Orphan Drug Designation of GV1001 by the MFDS for the treatment of Progressive Supranuclear Palsy (KR)

Completion of Patient Recruitment for Global Phase 2 Clinical Trial for Alzheimer’s Disease (US, EU)

Announcement of Topline Results for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

IND Approval for Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

EU IND Approval for Phase 2 Clinical Trial for Alzheimer’s Disease (7 European Countries)

Signing of Domestic License Agreement with Samsung Pharm Co., Ltd. for Alzheimer’s Disease Drug Development

Announcement of Phase 3 Clinical Trial Results for Benign Prostatic Hyperplasia (KR)

Approval of IND for Clinical Extension of Phase 2 Clinical Trial for Progressive Supranuclear Palsy (KR)

IND Approval for Phase 3 Clinical Trial for Alzheimer’s Disease (KR)

Initiation of Global Phase 2 Clinical Trial for Alzheimer’s Disease (US)

FDA IND Approval for Phase 2 Clinical Trial for Alzheimer’s Disease (US)

Announcement of Phase 2 Clinical Trial Results for Alzheimer’s Disease (KR)

Announcement of Phase 3 Clinical Trial Results for Pancreatic Cancer (KR)

Announcement of Phase 3 Clinical Trial Results for TeloVac (UK)

Execution of Management Rights Transfer Agreement with Samsung Pharm Co., Ltd. (Inclusion as an Affiliated Company)

Conditional Approval for the Pancreatic Cancer Immuno-Oncology Drug RIAVAX (KR)

Approval of IND for Phase 3 Clinical Trial for Pancreatic Cancer (KR)

Signing of Domestic License Agreement for RIAVAX with Samsung Pharm Co., Ltd.

Announcement of Phase 2 Clinical Trial Results for Benign Prostatic Hyperplasia (KR)

Company Establishment

KOSDAQ Market Listing

Acquisition of GemVax AS

Acquisition of Teloid